Get the Stockscreener App
39.01
0.10%
-0.04
After Hours:
39.17
0.16
+0.41%
10 X Genomics Inc stock is traded at $39.01, with a volume of 2.77M.
It is down -0.10% in the last 24 hours and up +27.03% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$39.05
Open:
$39.28
24h Volume:
2.77M
Relative Volume:
0.93
Market Cap:
$4.95B
Revenue:
$638.78M
Net Income/Loss:
$-22.66M
P/E Ratio:
-223.68
EPS:
-0.1744
Net Cash Flow:
$122.18M
1W Performance:
+9.18%
1M Performance:
+27.03%
6M Performance:
+134.72%
1Y Performance:
+199.85%
1-Day Range:
$38.19
$39.83
1-Week Range:
$34.57
$40.08
52-Week Range:
$11.16
$40.08
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
39.01 | 4.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
192.74 | 28.83B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
69.03 | 13.69B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
60.27 | 10.40B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
95.31 | 7.55B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
84.05 | 6.42B | 646.34M | -512.40M | 202.76M | -6.6871 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
Piper Sandler raises 10X Genomics stock price target on clinical pivot - Investing.com UK
10x Genomics stock hits 52-week high at 37.58 USD - Investing.com
Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS Insider - GlobeNewswire Inc.
10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ) - TradingView
1KJ Forecast — Price Target — Prediction for 2027 - TradingView
10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ) - TradingView
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor - Yahoo Finance
Price to earnings forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ) - TradingView
Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG) - TradingView
Enterprise value to EBIT forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10X Genomics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
10x Genomics Inc Class A Actuals & Estimates (LSE:0A88) - TradingView
Enterprise value to EBITDA forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (BIVA:TXG) - TradingView
Price to sales forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
TXG Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com - Investing.com Australia
Form 4 10X Genomics Inc For: 24 June By Investing.com - Investing.com Australia
10x genomics CEO Serge Saxonov sells $1.03m in stock - Investing.com
10x Genomics Insider Sold Shares Worth $1,033,269, According to a Recent SEC Filing - marketscreener.com
10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan - Stock Titan
Why Is 10x Genomics (TXG) Stock Soaring Today - Yahoo Finance
Price to book forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10X Genomics Inc (TXG) Institutional Confidence - TradingKey
10X Genomics stock hits 52-week high at 36.0 USD By Investing.com - Investing.com Australia
10X Genomics stock hits 52-week high at 36.0 USD - Investing.com
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
10x Genomics boosts single cell proteomics with acquisition of Proteintech Genomics - SelectScience
Insider Sell: Shehnaaz Suliman Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades - Stock Titan
TXG - Finviz
10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration - BioPharma APAC
10X Genomics stock rises on Cleveland Clinic partnership - Investing.com
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - BioSpace
10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocus
10x Genomics and Cleveland Clinic Collaborate to Advance Researc - GuruFocus
10X Genomics (TXG) Stock Surges 4% Following Cleveland Clinic Bladder Cancer Research Agreement - Blockonomi
10x Genomics, Inc and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - marketscreener.com
10X Genomics stock rises on Cleveland Clinic partnership By Investing.com - Investing.com India
10x Genomics partners with Cleveland Clinic on bladder cancer study By Investing.com - Investing.com Nigeria
10x Genomics partners with Cleveland Clinic on bladder cancer study - Investing.com
10X Genomics Inc (TXG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
10X Genomics Inc (TXG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
10X Genomics Inc (TXG) Valuation: PE, PB & Fair Value Analysis - TradingKey
10X Genomics Inc (TXG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
10x Genomics, Cleveland Clinic study aims to predict bladder cancer treatment response - Stock Titan
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SULIMAN SHEHNAAZ | Director |
Jun 16 '26 |
Sale |
32.63 |
5,723 |
186,756 |
31,722 |
9.47%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):